Biopharmaceutical company developing therapies for eye diseases and conditions.
Ocular Therapeutix, Inc., a dynamic biopharmaceutical company headquartered in Bedford, Massachusetts, specializes in formulating, developing, and commercializing innovative therapies for various eye diseases and conditions. Leveraging its advanced bioresorbable hydrogel-based formulation technology, the company is at the forefront of creating treatments that address critical needs in ophthalmology.
Among its pioneering products is ReSure Sealant, an ophthalmic device designed to prevent wound leaks in corneal incisions following cataract surgery. Additionally, Ocular Therapeutix markets DEXTENZA, an innovative dexamethasone ophthalmic insert used to manage post-surgical ocular inflammation and pain after ophthalmic surgery, as well as allergic conjunctivitis.
Ocular Therapeutix is actively advancing a robust pipeline of novel therapies. This includes OTX-TKI, an intravitreal implant containing axitinib currently undergoing phase 1 clinical trials for treating wet age-related macular degeneration and other retinal diseases. The company is also progressing OTX-TIC, an intracameral implant featuring travoprost, in phase 2 clinical trials for open-angle glaucoma or ocular hypertension.
Further expanding its portfolio, Ocular Therapeutix is developing OTX-CSI, a cyclosporine intracanalicular insert that completed phase 2 clinical trials for dry eye disease treatment, and OTX-DED, a dexamethasone intracanalicular insert in phase 2 clinical trials for managing dry eye disease symptoms. Collaborative partnerships with industry leaders such as Regeneron Pharmaceuticals and AffaMed Therapeutics highlight Ocular Therapeutix's commitment to advancing therapeutic options in ophthalmology, ensuring continuous innovation and patient-focused solutions in eye care.